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Abstract
Background: Translational errors can result in bypassing of the main viral protein reading frames and the production of
alternate reading frame (ARF) or cryptic peptides. Within HIV, there are many such ARFs in both sense and the antisense
directions of transcription. These ARFs have the potential to generate immunogenic peptides called cryptic epitopes (CE).
Both antiretroviral drug therapy and the immune system exert a mutational pressure on HIV-1. Immune pressure exerted by
ARF CD8
+ T cells on the virus has already been observed in vitro. HAART has also been described to select HIV-1 variants for
drug escape mutations. Since the mutational pressure exerted on one location of the HIV-1 genome can potentially affect
the 3 reading frames, we hypothesized that ARF responses would be affected by this drug pressure in vivo.
Methodology/Principal findings: In this study we identified new ARFs derived from sense and antisense transcription of
HIV-1. Many of these ARFs are detectable in circulating viral proteins. They are predominantly found in the HIV-1 env
nucleotide region. We measured T cell responses to 199 HIV-1 CE encoded within 13 sense and 34 antisense HIV-1 ARFs. We
were able to observe that these ARF responses are more frequent and of greater magnitude in chronically infected
individuals compared to acutely infected patients, and in patients on HAART, the breadth of ARF responses increased.
Conclusions/Significance: These results have implications for vaccine design and unveil the existence of potential new
epitopes that could be included as vaccine targets.
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Introduction
CD8
+ T cell responses are a major component in the immune
control of HIV-1 replication [1,2,3,4]. Primate studies suggest that
the breadth and magnitude of the vaccine-induced CD8
+ T cell
response correlates with viral load [5]. In the Step Trial that failed
to demonstrate efficacy, the Merck trivalent vaccine induced a low
number of CD8
+ T cell epitope responses per vaccinee (with a
median of three epitopes), suggesting that to be effective, vaccines
should induce a greater number of T cell responses [6].
HIV-1 infected cells are recognized by the CD8
+ T cell receptor
(TCR) through viral peptides presented on MHC-I molecules.
Most of the HIV-1 epitopes described have been identified in
HIV-1 proteins encoded by primary open reading frames (ORFs)
of the viral genome [7,8,9,10,11,12]. Aside from these ‘‘traditional
epitopes’’, a new type of epitopes derived from frame-shifted
proteins, called alternative reading frame (ARF) epitopes or cryptic
epitopes (CE), have been reported for influenza virus [13,14],
malignancies [15,16,17,18], and an autoimmune disease [19].
ARF expression may be explained by several transcriptional and
translational mechanisms [20]: ribosomal frame-shifting [21],
cryptic promoter activation, internal ribosomal entry sites [22],
initiation codon scan-through [23], doublet decoding alternative
splicing patterns [24], and initiation from non-AUG codons [25].
These nontraditional Cytotoxic T Lymphocyte (CTL) epitopes
are generated during HIV-1 and/or SIV infections
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epitopes originates from antisense (39 to 59) RNA transcription -
such antisense transcripts have been identified in HIV-1 infections
[33,34,35], and CEs derived from these antisense RNA have been
previously reported in SIV and HIV-1 infections [26,28,30]. CD8
+
specific T cells against HIV-1 CE could potentially contribute to
viral control in vivo [36]. In vitro studies show that SIV ARF
epitope–specific CTLs are able to select for viral escape variants
[30]. These ARF-derived peptides could therefore be an important
source of epitopes and could be used in an HIV-1 vaccine to
broaden the spectrum of the CD8
+ T cell responses.
To date, many studies have shown that immunological pressure
exerted by CTL shapes HIV-1 sequences by selecting for CTL
escape mutations [32,37,38,39]. HAART has also been described
to select HIV-1 variants for drug escape mutations
[40,41,42,43,44,45,46,47,48]. More recently, there has been some
evidence that emergence of drug resistance mutations can
potentially abolish HIV-1 CTL responses [49].
In this regard, we anticipated that ARFs would be affected by
immunological and drug pressure in vivo. Immune pressure exerted
by the ARF CD8
+ T cells on the virus has already been reported
in vitro [30]. Since the mutational pressure exerted on one location
of HIV-1’s genome can potentially affect each of the 3 reading
frames, ARF expression could be affected by HAART. HAART
mutational pressure on the virus could therefore be responsible for
the mutation or conservation of the genome of certain traditional
proteins or could disturb the expression of certain locations on
HIV-1’s genome, influencing ARF expression and escape from
ARF CTL responses.
In this study, we evaluated the influence of HAART on HIV-
1 ARF T cell responses over the course of HIV-1 infection. We
identified new cryptic epitopes derived from sense and antisense
transcription of HIV-1. To evaluate the effect of HAART on the
ARF T cell responses, we tested PBMCs from HIV-1 acutely
infected patients enrolled in a HAART interruption program and
HIV-1 chronically infected patients before and after HAART
introduction. We report that ARF responses were more frequent
and stronger in magnitude in chronically infected individuals
compared to acutely infected patients, and importantly that
HAART increased the breadth of the ARF responses. Our results
indicate that CE could potentially be used to increase the breadth
of an HIV-1 vaccine response.
Materials and Methods
Subjects
All subjects were recruited at the University of California, San
Francisco (UCSF), and were at least 18 years of age at the time of
sample collection. All samples were obtained according to
protocols approved by the Institutional Review Board (IRB) at
UCSF. Written informed consent was obtained from all subjects,
according to the Declaration of Helsinki. In order to study the
effect of HAART on ARF responses, IFN-c ELISPOT assays were
conducted in 2 different cohorts: the ‘‘OPTIONS cohort’’ with
acutely infected individuals, and the ‘‘SCOPE cohort’’ with
chronically infected individuals.
The OPTIONS cohort consists of subjects in acute or early
HIV-1 infection, with approximately 90% enrolled within 6
months of acquiring HIV-1 infection. For the purposes of this
manuscript, subjects in this cohort as designated as ‘‘acute’’ or
‘‘acutely infected’’ to help distinguish them from chronically
infected subjects. Cryopreserved PBMC samples were taken from
subjects enrolled in the OPTIONS cohort who had undergone a
treatment interruption study. To qualify for the treatment
interruption (TI) study, participants must have initiated antiretro-
viral therapy within 6 months of HIV-1 seroconversion, received
treatment for at least 24 weeks, and maintained viral loads (VL)
below 75 copies/mL for at least 8 weeks prior to entering the
protocol. The treatment interruption (TI) protocol was approved
by the UCSF IRB, and was designed for patients who initiated
antiretroviral therapy in early HIV-1 infection. Under this
protocol, treatment would be re-initiated if viral load exceeded
certain thresholds (.200,000 copies/mL at any time or .50,000
copies/mL between weeks 4 and 7 of TI). PBMC from each
individual was assayed at an early time-point on HAART, with
undetectable viral load, and at a later time-point after HAART
interruption, with high viral load. Out of 28 acute patients, we
tested the 2 time-points (before and after HAART interruption) for
25 patients. We were unable to follow 3 patients at the time-point
before HAART interruption.
HIV-1-infected adults were sampled from the Study of the
Consequences of the Protease Inhibitor Era (SCOPE), a clinic-
based cohort of over 1000 chronically HIV-1-infected individuals
at the University of California San Francisco. Chronically infected
individuals were tested at an early time-point before HAART
treatment with high viral load, and at a later time-point on
HAART with undetectable viral load. Out of 21 chronic patients,
18 patients were tested before and after HAART introduction. For
2 patients we only tested the sample before HAART introduction
and for 1 patient we only tested the sample after HAART
introduction. A description of the cohorts used is depicted in
Table 1. Table S1 depicts the viral load, CD4
+ and CD8
+ T cell
counts for each patient in each group.
HIV-1 negative, healthy blood donors provided PBMC for
control assays (N=12). No positive CE responses were noted in
any healthy blood donor.
In silico Detection of Alternate Reading Frames
Geneious Pro software was used to identify alternative open-
reading frames (ORF) starting with an AUG codon in HIV-1
HXB-2 strain. Both forward and reverse ORFs were identified.
Forward ORFs with significant similarity to known HIV proteins
were eliminated based on batch BLAST searches with manual
editing. Out of the 82 forward ORFs identified, 13 did not have
significant similarity via BLAST to known HIV proteins. This
resulted in the selection of 13 forward ORFs and 70 reverse ORFs
for further analysis (Table S2). In the BLAST searches for the 13
selected forward ORFs, 12 generated short hits against small
numbers of circulating viral sequence accessions in the NCBI nr
protein database (Table S3). These hits did not prompt rejection of
the ORF from further consideration, because of low bit scores, and
high e-values relative to those ORFs that represented canonical
coding sequence for the virus. For these hits, the geographic origin
of the sequence, location within the HIV-1 genome, and any data
pertinent to the mechanism by which this aberrant sequence may
have arisen were recorded. We believe these sequences to be
examples of the incorporation of ARF regions into circulating viral
sequences isolated from HIV-1 positive subjects.
In silico Peptide Prediction
In silico T cell immunogenicity prediction methods were used to
identify 9-mer peptide epitopes with potential to be processed by
cells, transported into the ER by TAP and bind to HLA molecules
in the HLA-B58, A2, and B7 super-families. Peptides were
identified within the 13 selected forward and 70 reverse HIV-1
alternate reading frames with NetCTL 1.2 software (http://www.
cbs.dtu.dk/services/NetCTL/). All forward ORFs were batched
and submitted together to prioritize the highest scoring peptides
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epitopes (N=22) for HLA-B58, A2, and B7 super-types were
selected for peptide synthesis.
Reverse ORFs peptides were also submitted for batch scoring
and were prioritized by combining the NetCTL score with
additional data regarding previous evidence of ORF expression,
ORF length, amino acid similarity to ARF epitopes detected in
SIV, and proximity to the 39 LTR.
Following peptide selection, candidate peptides were again
searched using BLAST against a custom database consisting of
HXB-2 and consensus B HIV-1 protein sequences gathered from
the Los Alamos National Lab HIV sequence databases. Peptides
from both forward and reverse reading frame ORFs were included
in these searches because any similarity that we expected to detect
would have resulted from spurious matches of amino acid
sequences within peptides. Peptides were classified according to
the numbers of amino acids in common with an HXB-2 and/or
consensus B amino acid sequence. Peptides with 5 or fewer amino
acids in common were classified as not significantly similar for the
purposes of T cell recognition. Peptides with 6 or more amino
acids in common are reported.
199 ARF peptides (forward and reverse ORF) were tested: 22
peptides from 13 identified forward ORF (6 predicted HLA-A2, 5
predicted HLA-B7, and 11 predicted HLA-B58 super-type
epitopes), the 2 Tat and Rev splice variant peptides previously
published [32], and 175 reverse ORF peptides from 34 identified
reverse ORF (80 predicted HLA-A2, 38 predicted HLA-B7, and
60 predicted HLA-B58 super-type epitopes) (Figure 1).
Peptide Synthesis
Peptides were synthesized on NEP array plates (96 wells plates),
with 75% purity average at a 2.5 mmol scale with a mass
spectrometry analysis of 5 peptides per plate to ensure successful
synthesis and positive identification. To evaluate classic HIV-1 T
cell responses, a pool of peptides from HIV-1 Gag p24 full protein
was used. Table S4 lists the sequences of the ARF individual
peptides used in this study and Table S5 lists the content of each
ARF pool tested.
IFN-c ELISPOT Assays
Immune responses were measured by IFN-c ELISPOT, as
previously described [38]. Data represent the average of two
replicate wells minus the average of all negative (no peptide) wells,
and are reported as spot-forming cells (SFCs) per million PBMCs,
with 100,000 cells added per well. Responses were considered
positive if the SFC count was greater than 5 spots (50 SFC per
million PBMCs) and greater than twice the background. Peptides
were tested at 5 mM/well.
To minimize variability, the same individual ran all experiments
and the two time-points from the same patient (‘‘on’’ versus ‘‘off’’
HAART) were tested on the same day.
Statistical Analysis
Statistical comparisons were performed using repeated mea-
sures logistic regression models. The fixed effects parameters in the
model were indicators of ‘‘On’’ versus ‘‘Off HAART’’, ‘‘Acute’’
versus ‘‘Chronic’’ patients, and the interaction of these two factors.
Random effects were used for both study subject and for peptide
pool to account for the intra-response correlations. Analyses were
performed using Stata 12.
Results
ARF Sequences are Found in Viruses with Gross Deletions
or Originating in Geographic Regions with a High
Prevalence of Recombinants
We found relatively small numbers of short matches with HIV-1
sequences while eliminating candidate ARF regions for structural
and accessory proteins. Matches represented circumstances where
ARF amino acid sequences were incorporated into predicted
sequences for viral proteins. Alternatively, these sequences may
possibly represent sequencing errors, indels erroneously intro-
duced into the reported nucleic acid sequence, resulting in a
frameshift mutation downstream. We noted the geographic origin,
the region of the HIV-1 genome in which the hit was found, gross
deletions, circulating recombinant forms or other major features of
the sequence to determine causative factors associated with the
inclusion of ARF regions in HIV-1 sequences. No mechanism for
the incorporation of the ARF was discernable for the majority of
ARF sequences detected (70%, referenced in Table S2). Amongst
sequences with an attributable origin, over half were associated
with either a recombination event or the presence of circulating
recombinant forms (Figure 2A). ARFs were also associated with
gross deletions, truncations, and point mutations (Figure 2A).
ARF Sequences are Skewed in Distribution
Predominantly in the HIV-1 Env Nucleotide Region
We investigated the genomic region that served as the source of
ARF sequences. If incorporation of ARF sequences were a purely
random event, the frequency of incorporation would be expected
Table 1. Patients’ characteristics.
Patient group
Number of
patients
Number of
additional
patients
Total number of
tested samples
Mean CD4
+ T cell
count (cells/mm
3)
Mean CD8
+ T cell
count (cells/mm
3)
Mean HIV-1 plasma
viral load (copies/mL)
Acute On HAART Early
Time-point
25 0 25 771 733 59
Acute Off HAART Later
Time-point
25 3 28 625 999 117,000
Chronic Before HAART
Early Time-point
18 2 20 328 1,439 545,000
Chronic On HAART
Later Time-point
18 1 19 482 1,227 52
Table depicts whether patients were HIV-1 acutely or chronically infected, stage of treatment, the number of patients used in the study, the number of extra patients
included in the study, total number of samples tested, mean frequency of CD4
+ and CD8
+ T cells (cells/mL) and viral load (copies/mL).
doi:10.1371/journal.pone.0039311.t001
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coding nucleotide sequence for structural proteins of the virus
particle (Figure 2B). We determined that the major contributor of
ARF sequences was from the HIV-1 env nucleotide region
(Figure 1), despite the fact that the env nucleotide region makes
only the second largest contribution to the coding sequence as a
percentage of the total of coding bases (36% of the coding
sequence: 2,751 of 6,878 total coding nucleotides), (Figures 2B and
2C). Interestingly, the HIV-1 pol nucleotide region is responsible
for 24% of the total circulating ARF sequences despite its
contribution of 44% of the coding sequence in the viral genome
(Figures 2B and 2C). To examine more precisely the nature of the
similarity between the HXB-2 reference, the ARF region and
circulating viral sequences, we created amino acid alignments for a
subset of matching accessions. We aligned one matching accession
from each region of the genome: the envelope region (Figure 2D),
the gag region (Figure 2E) and the pol region (Figure 2F). In each
region, amino acid alignments showed similarity both to the HXB-
2 reference sequence and to the alternate reading frame sequence,
but within distinct regions of each matching sequence (Figures 2D–
2F). These data indicate that the viral sequences identified in these
accessions are likely hybrids or chimaeras of standard and
alternate reading frame encoded sequences.
Peptides Originating from ARF Regions are
Distinguishable in Amino Acid Sequence from Peptides
Derived from HIV-1 Structural and Accessory Proteins
We searched our candidate ARF 9-mer peptides for similarity to
HIV-1 structural and accessory proteins. None of the ARF
peptides were identical in amino acid sequence to any known
structural or accessory protein regions of HIV-1. All ARF-derived
peptides differed by two or more amino acids from their closest
match in a structural or accessory protein of HIV-1.
B7ORF70ML9, the peptide that matched at 7 of 9 amino acids
was derived from ORF 70 and was a part of Pool #2. There were
also four peptides that matched at 6 of 9 amino acids
(B7ORF70LV9, B7ORF88SL9, A2ORF97LV9 and
A2ORF97CI9 were derived from ORF 70, ORF 88 and ORF
97, respectively). ORF 70 is a Forward ORF, ORFs 88 and 97 are
Reverse ORFs. The ORF 88 peptides were a part of Pool #13.
The ORF 97 peptides were a part of Pool #15. As a forward
reading frame ARF, ORF 70 was included in our searches of the
BLAST databases for ARF incorporation (Table S3). There were
5 hits against this ORF, indicating that ORF 70 is detectably
incorporated into circulating viral sequences. The two peptides
with BLAST hits within this ARF are similar to Vif amino acids
162–169, which is a previously identified HLA-B7 restricted
epitope in the Los Alamos database. However, significant
similarity does not extend outside this small region, so it does
Figure 1. HIV-1 genome (HXB-2 strain), and localization of the 47 alternative reading frames (ARF). Figure depicts all 199 ARF-tested
peptides. These include 13 forward ARF within frames 1, 2 or 3 (in green) and 34 reverse ARF within frames -1, -2 or -3 (in purple). HIV-1 classically
defined encoding genes are shown in blue.
doi:10.1371/journal.pone.0039311.g001
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PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e39311Figure 2. Alternate reading frame-encoded amino acids in circulating viral sequences. A) Distribution of known mutant origins across viral
ARF sequences attributable to a particular cause based on information associated with the sequence accession the NCBI nr protein database
presented in Table S2. B) Composition of viral coding sequence computed as a percentage assigned to the coding sequence for the Env, Gag, Pol
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tests.
HIV-1 Acutely Infected Individuals on HAART Mount
Detectable Responses Against ARF Pool Peptides
To assess if ARF T cell responses occur early after HIV-1
infection, we tested PBMC from HIV-1 acutely infected individ-
uals with ARF peptides, and detected the production of IFN-c in
an ELISPOT assay. In order to show the breadth of the responses,
Figure 3A depicts the number of detectable responses against the
ARF pool peptides tested in patients ‘‘On HAART’’ (blue bars)
and ‘‘Off HAART’’ (red bars). For acute subjects, there were a
total of 6 responses ‘‘On HAART’’ (1.1% of all wells) versus 17
responses ‘‘Off HAART’’ (2.8%) (p=0.06 by repeated measures
logistic regression). We detected 3 independent responses against
ARF peptide pools #2 and #12, followed by pools #8, #14 and
#19. Most peptide pools only elucidated one detectable response.
It is not possible to discern whether the responses seen in pools 2,
8,12, 14, and 19 in Figure 3A are due to cryptic epitopes or to
epitopes with significant homology to the main HIV-1 proteins
(peptides P2–407, P2–410; P8–462; P12–490, P12–493; P14–515,
P19–569). Figure 3B illustrates the number of ARF peptide pool
responses detected in each individual patient tested ‘‘On
HAART’’ (blue bars) and ‘‘Off HAART’’ (red bars). Patients
#2, #7 and #27 mounted 3 effective ARF responses while off
HAART and, in contrast, in patient #5, we did not detect any
responses while off HAART, but detected 3 while on HAART.
Out of the 25 patients with undetectable VL and at an early time-
point after infection, 4 mounted a detectable response against ARF
peptides (patients #4, #5, #18 and #25) with an average of
129 SFU (Figure 3). We also determined effective T cell responses
against HIV-1 Gag p24 peptides and found it to be on average
315 SFU on 12% of responders (3/25) (data not shown).
HAART Interruption is Associated with an Increase in
Frequency and Magnitude of ARF Responses
To evaluate whether HAART could play a role in impacting
ARF responses in acutely infected patients, we tested a cohort of
28 patients enrolled in a controlled HAART interruption
program. Early time-points before HAART interruption were
initially tested in 25 of these patients. Figure 4 illustrates the
detectable responses against the different ARF pool peptides in
patients while On HAART (blue bars), or Off HAART (red bars).
Analysis of responses at later time-points after HAART interrup-
tion and with high VL revealed 9 out of 28 patients (32%
responders) mounted an effective response against the ARF
peptide pools with an average of 233 SFU. 14 out of 28 patients
(50% responders) had an effective response against HIV-1 Gag
p24 peptides with an average response of 777 SFU (data not
shown). The data demonstrate that acutely infected patients
mount responses against ARF peptides. Overall, 13 out of 28
patients tested (46%) show responses against one or several ARF
pools. In this cohort study, patients were enrolled in a controlled
HAART interruption program, and responses are rare in patients
on HAART (16%), but increase after the interruption of therapy
(32%). In addition, the magnitude of ARF responses increased
with the interruption of HAART (128 SFU in patients on
HAART to 233 SFU in patients off HAART). Interestingly, the
dynamics of ARF responses also changed before and after
HAART interruption. In this regard, we report that all responses
against ARF peptides in patients on HAART were not maintained
after the interruption of the treatment. On the other hand, patients
on HAART, but with no effective ARF responses were able to
mount ARF T cell responses after treatment interruption.
T Cell Responses Against ARF Pool Peptides are Stronger
in HIV-1 Chronically Infected Individuals
Next, we investigated whether chronically infected patients
could still mount effective responses against ARF pool peptides.
For this purpose we tested chronically HIV-1 infected subjects at
an early time-point before HAART treatment with high viral load
and the same patients at a later time-point while on HAART. In
order to show the breadth of the measurable responses, Figure 5A
depicts the number of detectable responses against the ARF pool
peptides tested in patients ‘‘Before HAART’’ (grey bars) and ‘‘On
HAART’’ (black bars). For chronic subjects, there were a total of
29 responses on HAART (6.9% of all wells) versus 8 responses
before HAART (1.6%) (p,0.01 by repeated measures logistic
regression). In parallel, Figure 5B shows the number of ARF
responses detected for each individual chronic patient tested. We
found that 20% of the patients tested with high viral load (4/20)
responded against ARF pool peptides before the introduction of
HAART (Figure 5B). Average ARF responses in this group were
2101 SFU, compared to 1009 SFU against HIV-1 Gag p24
observed in 45% of responders (9/20) (data not shown). Overall,
chronically HIV-1 infected patients present stronger and more
frequent responses against several ARF pools compared to acutely
HIV-1 infected. This suggests that ARF responses increase with
the duration of infection.
The Introduction of HAART in Chronically HIV-1 Infected
Patients Increases the Breadth of ARF Responses
To investigate if HAART had the same impact on ARF
responses in chronically HIV-1 infected individuals as it did in
acutely infected, we tested the same patients at a later time-point
on HAART and with undetectable viral load. We detected
effective responses in 26% of the patients tested (5/19) against
ARF pool peptides at the later time-point while on HAART with
undetectable VL (Figure 6). Although the frequency of responses
was higher in patients on HAART, the average magnitude of the
responses is lower (978 SFU), compared to the responses against
poly-proteins based on nucleotide base counts for a particular gene region compared to the total nucleotide count for the structural genes of the
virus. Gag comprises 1,503 nt of the total of 6,878 nt of structural gene sequence; Pol comprises 3,139 nt of the total; Env comprises of 2,571 nt of
the total. This is the distribution of origins within the genome that would be expected if originating events for the incorporation of ARF and their
detection in circulating HIV-1 viral sequences were distributed randomly throughout the genome. C) The distribution of ARF incorporated into
circulating viral sequences that was observed in our searches of NCBI nr protein database for ARF sequences in circulating HIV-1 viral sequences. The
percentages were computed by dividing the number of BLAST hits with ARF sequence incorporated into a given gene region by the 123 total hits
examined. D) A three-way alignment between the HXB-2 reference sequence for the Env region, the accession AAL78125.1 and the alternate reading
frame encoded ORF 67. E) A three-way alignment between the HXB-2 reference sequence for the Gag region, the accession AEQ21252.1 and the
alternate reading frame encoded ORF 3. F) A three-way alignment between the HXB-2 reference sequence for the Pol region, the accession
CAF29000.1 and the alternate reading frame encoded ORF 23. All three-way alignments were generated by combining two pair-wise alignments
created in Geneious, followed by manual editing. Note each accession is similar to both the HXB-2 reference sequence for the structural proteins and
the alternate reading frame encoded sequence, but not to both sequences simultaneously within the same region of the sequence.
doi:10.1371/journal.pone.0039311.g002
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response of 658 SFU).
Although ARF responses after HAART were diminished in all
cases, they still remained at weak to moderate levels, suggesting
that cryptic epitopes are still presented, even under suppressive
HAART regimens. Overall, we observed a higher number of ARF
responses after HAART introduction, suggesting that HAART
favors the emergence of new CE responses and increases the
Figure 3. Breadth of ARF responses in acutely infected patients. A) Number of detectable responses observed for each individual ARF
peptide-pool tested. B) Number of ARF peptide pools that induced detectable responses in each acutely infected individual. Blue bars represent
patients On HAART and red bars represent patients Off HAART. We were unable to follow patients #26, #27 and #28 before HAART interruption.
doi:10.1371/journal.pone.0039311.g003
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patient #40, while responses were diminished in magnitude, the
number of CE recognized was greater (Figure 7). In this patient
before HAART, we detected 2 strong responses against ARF pool
peptides #1 and #8. At a later time-point when this patient was
on HAART, we were still able to detect the same responses against
these 2 pool peptides, but at a lower magnitude. Interestingly, we
detected 4 new ARF responses, which were absent before
treatment. Responses against alternative spliced variants from
TAT or REV (pool #1), previously described in Elite Controllers,
were only found in one chronically infected patient, before
HAART and on HAART.
Discussion
In this study, we identified new cryptic epitopes derived from
sense and anti-sense transcription of HIV-1. We identified
virologic events associated with the incorporation of ARF
sequences into circulating viral sequences. Associated events such
as recombination, gross deletions and point mutations are
consistent with the plausible introduction of frameshift mutations
Figure 4. Overview of ARF responses in acutely infected patients. Out of 22 ARF peptide pools tested, 16 induced detectable responses.
Each individual graph depicts the intensity of responses measured in an ELISPOT assay against IFN-c (SFU/million PBMC) for each peptide in the
corresponding patient. Blue bars correspond to patients On HAART and red bars to patients Off HAART. Responders were only considered if the net
response against the peptide pool was .50 SFU (cut-off) over background and greater than twice the background.
doi:10.1371/journal.pone.0039311.g004
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incorporated into coding sequences is noteworthy for the fact that
it does not conform to the expectations associated with random
distribution of the originating events within the genome. The
distribution is not likely to be an effect of each gene region’s total
ARF content, as the HIV-1 env nucleotide regions was shown to
be the major contributor to known circulating viral ARF
sequences, despite containing the smallest percentage of total
ARF sequences within its bases. Thus, the env region makes a
disproportionally large contribution to the total number of
detected ARF sequences compared to its contribution to the total
coding sequence. Accessory protein coding regions also exist in this
area of the genome, limiting the number of reading frames that
could possibly contain ARFs without intersecting with coding
Figure 5. Breadth of ARF responses in chronically infected patients. A) Number of detectable responses observed for each individual ARF
peptide-pool tested. B) Number of ARF peptide pools that induced detectable responses in each chronically infected individual. Grey bars represent
patients Before HAART and black bars represent patients On HAART. Patients #47 and #48 were only tested before HAART introduction and patient
#49 was only tested after HAART.
doi:10.1371/journal.pone.0039311.g005
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PLoS ONE | www.plosone.org 9 June 2012 | Volume 7 | Issue 6 | e39311Figure 6. Overview of ARF responses in acutely infected patients. Out of 22 ARF peptide pools tested, 18 induced detectable responses.
Each individual graph depicts the intensity of responses measure in an ELISPOT assay against IFN-c (SFU/million PBMC) for each peptide in the
corresponding patient. Grey bars correspond to patients Before HAART and black bars to patients On HAART. Responders were only considered if the
net response against the peptide pool was .50 SFU (cut-off) over background and greater than twice the background.
doi:10.1371/journal.pone.0039311.g006
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events needed to create some of these accessory proteins may
enhance the incorporation of ARF into viral proteins. This novel
observation of incorporation of ARF regions into the Env protein
could have an impact on the overall plasticity of its amino acid
sequence. This plasticity makes a significant contribution to the
immune escape of the virus from the neutralizing effects of
antibodies targeting Env proteins.
The pol nucleotide region makes a disproportionally small
contribution to the total number of ARFs considering the size of
this coding region. This may imply constraints that do not permit
the incorporation of ARF. As antiretroviral drugs target this
region, it is interesting to consider how HAART could modify the
dynamics of ARF inclusion in the region.
These circulating, modified viral genomes, together with the
translational errors occurring in otherwise intact viral genomes as
described previously, are the likely sources for the epitopes that we
analyzed in this study. We implemented a number of measures to
exclude structural and accessory proteins encoded in standard
reading frames of HIV-1 by screening for BLAST similarity at the
ORF and peptide levels. None of the ARF-encoded peptides
shared more than 7 amino acids in common with any regions of
HIV-1 structural or accessory proteins. Five peptides from three of
the pools tested shared 6–7 amino acids in common with regions
of structural or accessory proteins of HIV-1. While it is important
to interpret the immunological results in light of this limited level
of similarity, exclusion of these peptides from our analysis was not
appropriate. Two of the most similar ARF-encoded peptides
originated from a region of alternate reading frame sequence that
was detectably incorporated into circulating viral sequences in the
NCBI databases. Thus, the immune systems of HIV-1 positive
individuals may be exposed to both the structural/accessory-
encoded and ARF-encoded variants of these peptides. Addition-
ally, these regions of amino acid similarity may help to elucidate a
population of T cells that are potentially cross-reactive between
ARF and standard reading frame-encoded peptides.
We evaluated the influence of HAART on HIV-1 ARF T cell
responses over the course of HIV-1 infection. In HAART-treated
patients, we observed that the frequency and magnitude of T cell
responses are higher in chronically infected individuals (26%,
978 SFU) when compared to acutely infected patients (16%,
129 SFU). This suggests that ARF responses increase over the
course of HIV-1 infection, and with time, HIV-infected cells have
a higher chance of producing and presenting ARF peptides. In
chronically HIV-1-infected individuals, HAART decreases the
magnitude of ARF responses (from 2100 SFU before to 978 SFU
after the introduction of HAART). When ARF responses were
analyzed at the individual level, HAART increased the breadth of
the responses, which may be due to the selective pressure exerted
by drugs on the virus, potentially facilitating the expression of
certain ARFs. In acutely infected patients enrolled in a HAART
interruption program, we found that HAART interruption favors
ARF responses. This could be explained by the fact that HAART
exerts a selective pressure on the virus with the emergence of new
ARF expression. These immunological results are interesting in
light of the relative deficit of ARF incorporation into Pol proteins
demonstrated by our database searches. HAART likely alters the
dynamics of selective forces acting on the pol nucleotide region
and may favor incorporation of some ARF that are otherwise
generally disfavored in the region. ARF responses are also present
in patients on HAART, even in the absence of detectable anti-
HIV-1 T cell responses (from the traditional reading frame),
suggesting that ARF products are produced in cells from a latent
reservoir. Thus, this therapy or vaccination strategy could
specifically target latently infected cells and help in eradication
strategies.
Dynamics of ARF Responses
Although certain pre-existing ARF responses disappeared after
the interruption of HAART, new ARF responses emerged. The
mechanism underlying ARF expression, mutation and conserva-
tion is complex and it involves direct and indirect effects of viral
strain and natural evolution within the host, as well as the specifics
of the HAART regimen together with patient’s intrinsic charac-
teristics. CTL and HAART both exert a selective pressure on
HIV-1 by selecting for CTL or drug escape mutations. The
mutational pressure exerted on one location of the HIV-1 genome
potentially affects the 3 reading frames, and therefore affects
ARFs. ARF T cell responses may therefore be affected through
immunological pressure exerted by a classical HIV-1 epitope at
the same location, but on a different reading frame. Mutations in
one frame do not necessarily lead to the disappearance of an ARF
epitope. A non-synonymous change in the one coding frame
targeted by the selective pressure may account for a synonymous
Figure 7. ARF responses in one HIV-1 chronically infected patients before and on HAART. In the pie charts each color represents a pool of
immune response that the patient mounted against. Numbers inside the pie charts correspond to the magnitude of the response against the pool in
SFU/million PBMC.
doi:10.1371/journal.pone.0039311.g007
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nd or 3
rd frames where the ARF epitope is encoded.
Therefore, an ARF epitope may be conserved and maintained due
to the selective pressure on a different frame. HAART may shape
HIV-19s genome by exerting selective pressure on one or more of
the reading frames in a nucleotide region containing an ARF.
Therefore, targeting ARF epitopes, especially those that could help
the virus escape drug or immune pressure, could provide a new
tool to combat viral resistance.
ARF versus Classic HIV-1 Specific T Cell Responses
In comparison to ARF responses, classically known HIV-1 T
cell responses are higher and more frequent in acutely infected
individuals. However, in chronically infected patients, the
magnitude of ARF responses is similar to the responses to known
HIV-1 epitopes. In early infection, the magnitude of ARF
responses is below the responses observed for regular CTL HIV
responses. We could expect that compared to immune-dominant,
known HIV-1 epitopes, ARF peptides would be expressed and
presented at a lower density. The similar magnitude of ARF and
classic HIV-1 responses in chronically infected subjects could be
due to the accumulation with time of the production and
presentation of more ARF peptides and/or the viral escape to
classic HIV-1 CTL epitopes.
A Larger Spectrum of ARF Responses
Our data is probably under-estimating the spectrum of ARF
responses since we were not able to screen all of the potential
peptides encoded within each ARF, but instead used in silico
predicted epitopes. Because of limitations in cell numbers, we did
not test all the selected peptides for immune responses (in
particular, many potential antisense ARF identified on the 59
end of the genome, further from the 39 LTR). Other ARF without
conventional AUG start codons have been described [27,31,39]
and have not been explored in our present study.
An ARF Vaccine as a Site-directed HIV Mutagenesis Tool
Taking the phenomenon from a different perspective, the
mutational pressure exerted by ARF immune responses could be
used to mutate critical proteins of the virus, or to effectively limit
the possible mutations permissible in other reading frames. Within
the HIV genome, a region that is well conserved due to a high
fitness cost for viral protein mutations could potentially contain
ARF epitopes in the two other reading frames. Therefore, the
immune mutational pressure exerted by an ARF vaccine through
CE specific T cells could force the virus to mutate the area
containing the ARF epitopes, which would affect the crucial HIV
protein encoded in a different frame, rendering the virus defective.
ARF Responses and Viral Control
The duration of infection and HAART play a role on the
magnitude and breadth of ARF responses. As an observational
cross sectional study, our data does not show whether ARF
responses help in controlling HIV-1 infection. Previous studies
have shown that the magnitude of the CD8
+ T cell response
poorly correlates with immune control of HIV-1 infection [10,37]
whereas the breadth of the CTL response seems to be better
associated with viral control [50,51]. Previous in vitro studies have
shown viral suppression by ARF CTLs [30], and viral escape from
an ARF CD8
+ T cell response has been described in monkey
studies, supporting their immunogenicity in vivo [30]. Recently,
human data suggested that responses to ARF-encoded HIV-1
epitopes contribute to viral control in vivo, and drives viral
evolution on a population level [26,27]. We have previously
reported more frequent CE responses in patients with well-
controlled HIV-1 infection [32].
ARF responses could potentially be used as a diagnostic tool to
monitor HIV-1 immunity through T cell responses against ARF
peptides, and could be a surrogate marker to measure the ability of
an anti-retroviral drug regimen to work against the latent
reservoir.
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